ZIOPHARM Oncology Inc. | Mutual Funds
Mutual Funds that own ZIOPHARM Oncology Inc.
Legg Mason Opportunity Trust
3,690,000
2.59%
3,690,000
0.57%
12/31/2016
Vanguard Total Stock Market Index Fund
3,138,443
2.2%
3,100
0%
07/31/2018
iShares Russell 2000 ETF
2,799,975
1.97%
-1,494
0.02%
09/06/2018
SPDR S&P Biotech ETF
2,705,664
1.9%
6,960
0.14%
09/06/2018
Vanguard Extended Market Index Fund
1,742,231
1.22%
0
0.01%
07/31/2018
Vanguard Small Cap Index Fund
1,632,026
1.14%
49,201
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
1,249,682
0.88%
0
0.03%
09/06/2018
Vanguard Small Cap Growth Index Fund
905,530
0.64%
4,099
0.01%
07/31/2018
Government Pension Fund - Global (The)
818,864
0.56%
-219,664
0%
12/31/2017
Fidelity Spartan Extended Market Index Fund
620,104
0.44%
0
0.01%
07/31/2018
| Address |
Parris Building
Boston Massachusetts 02129
United States
|
|
Employees
|
- |
| Website |
http://www.ziopharm.com |
| Updated |
07/08/2019 |
| ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA. |
